JP2012532899A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532899A5
JP2012532899A5 JP2012519900A JP2012519900A JP2012532899A5 JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5 JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5
Authority
JP
Japan
Prior art keywords
het
conr
hal
atoms
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519900A
Other languages
English (en)
Japanese (ja)
Other versions
JP5681182B2 (ja
JP2012532899A (ja
Filing date
Publication date
Priority claimed from DE102009033208A external-priority patent/DE102009033208A1/de
Application filed filed Critical
Publication of JP2012532899A publication Critical patent/JP2012532899A/ja
Publication of JP2012532899A5 publication Critical patent/JP2012532899A5/ja
Application granted granted Critical
Publication of JP5681182B2 publication Critical patent/JP5681182B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519900A 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体 Expired - Fee Related JP5681182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009033208A DE102009033208A1 (de) 2009-07-15 2009-07-15 Aminopyridinderivate
DE102009033208.1 2009-07-15
PCT/EP2010/003659 WO2011006567A1 (de) 2009-07-15 2010-06-17 Aminopyridinderivate zur behandlung von tumoren und entzündungskrankheiten

Publications (3)

Publication Number Publication Date
JP2012532899A JP2012532899A (ja) 2012-12-20
JP2012532899A5 true JP2012532899A5 (https=) 2013-08-29
JP5681182B2 JP5681182B2 (ja) 2015-03-04

Family

ID=42665826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519900A Expired - Fee Related JP5681182B2 (ja) 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体

Country Status (11)

Country Link
US (1) US8648201B2 (https=)
EP (1) EP2454253B1 (https=)
JP (1) JP5681182B2 (https=)
CN (1) CN102471317B (https=)
AR (1) AR077567A1 (https=)
AU (1) AU2010272920B2 (https=)
CA (1) CA2768169C (https=)
DE (1) DE102009033208A1 (https=)
ES (1) ES2534095T3 (https=)
IL (1) IL217467A (https=)
WO (1) WO2011006567A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159575A (en) * 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
US8420655B2 (en) * 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
CA2828578A1 (en) * 2011-03-04 2012-09-13 Lexicon Pharmaceuticals, Inc. Mst1 kinase inhibitors and methods of their use
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
CN104169275B (zh) * 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
JP6189434B2 (ja) * 2012-07-10 2017-08-30 アレス トレーディング ソシエテ アノニム ピリミジンピラゾリル誘導体
WO2014058685A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
WO2015006181A1 (en) 2013-07-11 2015-01-15 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
AU2015220427B2 (en) 2014-02-19 2017-09-21 Piramal Enterprises Limited Compounds for use as GPR120 agonists
AU2015293541B2 (en) 2014-07-25 2019-11-21 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
EP3191463B1 (en) * 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
AU2023228096A1 (en) * 2022-03-02 2024-10-17 Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Histamine h3 receptor antagonist and medical use thereof
CN121646587A (zh) * 2024-05-30 2026-03-10 深圳微芯生物科技股份有限公司 一种苯并咪唑类化合物、其制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
JP2009533327A (ja) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのc−METキナーゼ阻害剤
US8308245B2 (en) 2007-06-29 2012-11-13 Vekoma Rides Engineering B.V. Amusement device seat assembly
WO2009024825A1 (en) * 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
JP2011500778A (ja) * 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−083
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2012532899A5 (https=)
JP2012506389A5 (https=)
JP2014508811A5 (https=)
JP2011530545A5 (https=)
JP2010529051A5 (https=)
JP2013501047A5 (https=)
JP2012092103A5 (https=)
JP2010532768A5 (https=)
JP2014508753A5 (https=)
JP2012111953A5 (https=)
JP2018533593A5 (https=)
JP2012532901A5 (https=)
JP2010526025A5 (https=)
JP2010095546A5 (https=)
JP2009529540A5 (https=)
HRP20161103T1 (hr) Kemijski spojevi
JP2013542218A5 (https=)
AR078497A1 (es) Isoxazoles como antagonistas de los receptores de acido lisofosfatidico
RU2018116351A (ru) Пиримидиновое соединение
JP2009501198A5 (https=)
JP2012506896A5 (https=)
JP2010510177A5 (https=)
JP2015522650A5 (https=)
JP2013521295A5 (https=)
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias